BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, Garrote V, Vietto V. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2019;10:CD012552. [PMID: 31587256 DOI: 10.1002/14651858.CD012552.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Su X, Cai C, Wang Z, Tang M. Application Analysis of UPOINT System in Chinese Type III Prostatitis Patients: A Single Center Experience. Computational and Mathematical Methods in Medicine 2022;2022:1-7. [DOI: 10.1155/2022/9227032] [Reference Citation Analysis]
2 Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. Diagnostic and Management Strategies for Patients with Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Drugs Aging 2021;38:845-86. [PMID: 34586623 DOI: 10.1007/s40266-021-00890-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Liu H, Zhu X, Cao X, Chi A, Dai J, Wang Z, Deng C, Zhang M. IL-1β-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity. Stem Cell Res Ther 2021;12:514. [PMID: 34563249 DOI: 10.1186/s13287-021-02579-0] [Reference Citation Analysis]
4 Bryk DJ, Shoskes DA. Using the UPOINT system to manage men with chronic pelvic pain syndrome. Arab J Urol 2021;19:387-93. [PMID: 34552790 DOI: 10.1080/2090598X.2021.1955546] [Reference Citation Analysis]
5 Chen L, Zhang M, Liang C. Chronic Prostatitis and Pelvic Pain Syndrome: Another Autoimmune Disease? Arch Immunol Ther Exp (Warsz) 2021;69:24. [PMID: 34523016 DOI: 10.1007/s00005-021-00628-3] [Reference Citation Analysis]
6 Teoh JY, Wroclawski ML, Yuen S, Cheng B, Bertolo R, Castellani D, Gauhar V, Herrmann T. Re: Shedding light on polypragmasy of pain after transurethral prostate surgery procedures: a systematic review and meta-analysis. World J Urol 2021. [PMID: 34021778 DOI: 10.1007/s00345-021-03663-z] [Reference Citation Analysis]
7 Zhao B, Zheng J, Qiao Y, Wang Y, Luo Y, Zhang D, Cai Q, Xu Y, Zhou Z, Shen W. Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis. Transl Androl Urol 2021;10:1976-87. [PMID: 34159078 DOI: 10.21037/tau-21-139] [Reference Citation Analysis]
8 Mykoniatis I, Kalyvianakis D, Zilotis F, Kapoteli P, Fournaraki A, Poulios E, Hatzichristou D. Evaluation of a low-intensity shockwave therapy for chronic prostatitis type IIIb/chronic pelvic pain syndrome: a double-blind randomized sham-controlled clinical trial. Prostate Cancer Prostatic Dis 2021;24:370-9. [PMID: 32989261 DOI: 10.1038/s41391-020-00284-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Nikkola J, Holm A, Seppänen M, Joutsi T, Rauhala E, Kaipia A. Repetitive Transcranial Magnetic Stimulation for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Pilot Study. Int Neurourol J 2020;24:144-9. [PMID: 32615676 DOI: 10.5213/inj.1938258.129] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Xu W, Tang M, Wang J, Wang L. Identification of the Active Constituents and Significant Pathways of Cangfu Daotan Decoction for the Treatment of PCOS Based on Network Pharmacology. Evid Based Complement Alternat Med 2020;2020:4086864. [PMID: 32148541 DOI: 10.1155/2020/4086864] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI, Garrote V, Vietto V. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev 2019;10:CD012552. [PMID: 31587256 DOI: 10.1002/14651858.CD012552.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]